Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics Inc.

Soleno Therapeutics ( ($SLNO) ) has issued an update. On November 11, 2025, Soleno Therapeutics announced that its Board of Directors approved an a...

Soleno Therapeutics Announces $100M Share Buyback Plan

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $123.00. Kluska covers ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLNO	$45.11	+0.36%	1.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLNO	$45.11	+0.4%	1.31M
3
4
5
6

SLNO

SLNO

Latest News for SLNO

Get Soleno Therapeutics Inc. Data in Excel

Get Soleno Therapeutics Inc. Data in Excel